Lightlake Therapeutics, Inc. acquires a patent with the potential to establish a new treatment paradigm
to terminate addiction to legal and illegal drugs.Lightlake Therapeutics Inc (LLTP OTCBB) has acquired US Patent 5,587,381, entitled: ‘Method for terminating methadone maintenance through extinction of the opiate-taking responses’, using an opioid antagonist as treatment. The Patent also covers treatment for addiction to other legally available opioids and to stimulant drugs such as Cocaine and Amphetamines. Unmet Need Opiate addiction is a major worldwide health problem. Traditional treatments attempt to increase the addict's will power to withstand the craving for opiates but do